Institutional Investors Acquire Rs 777 Crore Stake in Corona Remedies via Block Deal
Sepia Investments and Anchor Partners sold a combined 7.34% stake in Corona Remedies worth approximately Rs 777 crore through block deals on June 17, 2026. HDFC Mutual Fund was the largest buyer, acquiring over half the shares, alongside institutional investors such as Aberdeen Group, Abu Dhabi Investment Authority (ADIA), Aditya Birla Sun Life Mutual Fund, WhiteOak Capital, Invesco, and Kotak Mahindra Mutual Fund. The transaction reflects strong institutional interest in the pharmaceutical company, whose shares rose nearly 3% following the deal.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is neutral (62/100). Lens Score 48/100 — moderate-to-low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- news18— balanced framing, neutral sentiment
- economictimes— balanced framing, neutral sentiment
AI Analysis
The articles primarily present financial and investment perspectives without political framing. Coverage focuses on institutional investors' transactions and market responses, representing viewpoints from investment firms and market analysts. There is no evident political bias, as the story centers on corporate share sales and acquisitions.
The tone across the articles is neutral to positive, emphasizing significant institutional interest and a subsequent rise in Corona Remedies' share price. The coverage highlights market activity and investor confidence without critical or negative commentary, reflecting a generally favorable sentiment toward the transaction.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.